629 related articles for article (PubMed ID: 25813688)
21. Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial.
Bill-Axelson A; Garmo H; Holmberg L; Johansson JE; Adami HO; Steineck G; Johansson E; Rider JR
Eur Urol; 2013 Dec; 64(6):920-8. PubMed ID: 23465517
[TBL] [Abstract][Full Text] [Related]
22. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.
Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Ruutu M; Bill-Axelson A;
Lancet Oncol; 2011 Sep; 12(9):891-9. PubMed ID: 21821474
[TBL] [Abstract][Full Text] [Related]
23. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer.
Walz J; Gallina A; Perrotte P; Jeldres C; Trinh QD; Hutterer GC; Traumann M; Ramirez A; Shariat SF; McCormack M; Perreault JP; Bénard F; Valiquette L; Saad F; Karakiewicz PI
BJU Int; 2007 Dec; 100(6):1254-8. PubMed ID: 17979925
[TBL] [Abstract][Full Text] [Related]
24. Management of older men with clinically localized prostate cancer: the significance of advanced age and comorbidity.
Hoffman KE
Semin Radiat Oncol; 2012 Oct; 22(4):284-94. PubMed ID: 22985811
[TBL] [Abstract][Full Text] [Related]
25. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
[TBL] [Abstract][Full Text] [Related]
26. Understanding the Use of Prostate Biopsy Among Men with Limited Life Expectancy in a Statewide Quality Improvement Collaborative.
Abdollah F; Ye Z; Miller DC; Linsell SM; Montie JE; Peabody JO; Ghani KR;
Eur Urol; 2016 Nov; 70(5):854-861. PubMed ID: 27113032
[TBL] [Abstract][Full Text] [Related]
27. Capture rate and representativity of The National Prostate Cancer Register of Sweden.
Tomic K; Berglund A; Robinson D; Hjälm-Eriksson M; Carlsson S; Lambe M; Stattin P
Acta Oncol; 2015 Feb; 54(2):158-63. PubMed ID: 25034349
[TBL] [Abstract][Full Text] [Related]
28. Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males.
Van Hemelrijck M; Ventimiglia E; Robinson D; Gedeborg R; Holmberg L; Stattin P; Garmo H
BMC Med Inform Decis Mak; 2022 Feb; 22(1):35. PubMed ID: 35135530
[TBL] [Abstract][Full Text] [Related]
29. The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis.
Löppenberg B; Dalela D; Karabon P; Sood A; Sammon JD; Meyer CP; Sun M; Noldus J; Peabody JO; Trinh QD; Menon M; Abdollah F
Eur Urol; 2017 Jul; 72(1):14-19. PubMed ID: 27174537
[TBL] [Abstract][Full Text] [Related]
30. Life expectancy estimates as a key factor in over-treatment: the case of prostate cancer.
Delpierre C; Lamy S; Kelly-Irving M; Molinié F; Velten M; Tretarre B; Woronoff AS; Buemi A; Lapôtre-Ledoux B; Bara S; Guizard AV; Colonna M; Grosclaude P
Cancer Epidemiol; 2013 Aug; 37(4):462-8. PubMed ID: 23623489
[TBL] [Abstract][Full Text] [Related]
31. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
[TBL] [Abstract][Full Text] [Related]
33. Patient comorbidity is associated with conservative treatment of localized prostate cancer.
Jespersen CG; Nørgaard M; Jacobsen JB; Borre M
Scand J Urol; 2015; 49(5):366-70. PubMed ID: 25903072
[TBL] [Abstract][Full Text] [Related]
34. Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer.
Linder BJ; Boorjian SA; Umbreit EC; Carlson RE; Rangel LJ; Bergstralh EJ; Karnes RJ
Int J Urol; 2013 Aug; 20(8):798-805. PubMed ID: 23278850
[TBL] [Abstract][Full Text] [Related]
35. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
Sammon JD; Abdollah F; Reznor G; Pucheril D; Choueiri TK; Hu JC; Kim SP; Schmid M; Sood A; Sun M; Kibel AS; Nguyen PL; Menon M; Trinh QD
Eur Urol; 2015 Jul; 68(1):32-9. PubMed ID: 25457017
[TBL] [Abstract][Full Text] [Related]
36. Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk.
Lunardi P; Ploussard G; Grosclaude P; Roumiguié M; Soulié M; Beauval JB; Malavaud B
World J Urol; 2017 Apr; 35(4):587-593. PubMed ID: 27443847
[TBL] [Abstract][Full Text] [Related]
37. Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study.
Holmström B; Holmberg E; Egevad L; Adolfsson J; Johansson JE; Hugosson J; Stattin P;
J Urol; 2010 Oct; 184(4):1322-7. PubMed ID: 20723940
[TBL] [Abstract][Full Text] [Related]
38. Degree of preservation of the neurovascular bundles during radical prostatectomy and urinary continence 1 year after surgery.
Steineck G; Bjartell A; Hugosson J; Axén E; Carlsson S; Stranne J; Wallerstedt A; Persson J; Wilderäng U; Thorsteinsdottir T; Gustafsson O; Lagerkvist M; Jiborn T; Haglind E; Wiklund P;
Eur Urol; 2015 Mar; 67(3):559-68. PubMed ID: 25457018
[TBL] [Abstract][Full Text] [Related]
39. Do older men benefit from curative therapy of localized prostate cancer?
Alibhai SM; Naglie G; Nam R; Trachtenberg J; Krahn MD
J Clin Oncol; 2003 Sep; 21(17):3318-27. PubMed ID: 12947068
[TBL] [Abstract][Full Text] [Related]
40. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
